In synovial fibroblasts, RVX-297 (1-30 μM; 24 hours) decreases the expression of pro-inflammatory genes [1]. Similar to pan-BET inhibitors that non-selectively bind BET BD, RVX-297 displaces BET proteins from sensitive gene promoters and inhibits the recruitment of active RNA polymerase II [1]. In vitro, RVX-297 decreases the gene expression of inflammatory mediators. In a dose-dependent way, RVX-297 suppresses the induction of the IL-6 gene in human U937 macrophages, mice primary B cells derived from the spleen, mouse BMDM, and THP-1 monocytes. With an IC50 of 0.4-3 μM, RVX-297 suppresses the expression of IL-1β in LPS-stimulated mouse BMDM. RVX-297 has an IC50 of 0.4 μM for inhibiting MCP-1 expression in unstimulated human PBMC. RVX-297 suppresses T cell antigen stimulation and IL-17 expression induction [1].

In an arthritic model caused by collagen in rats, RVX-297 (25–75 mg/kg; oral; once daily for 6 days) prevents disease advancement [1]. In mice with collagen-induced arthritis, RVX-297 (75–150 mg/kg) prevents the arthritis model's pathogenic advancement [1]. LPS-treated mice produce less cytokines when RVX-297 is administered [1].

RT-PCR[1]
Cell Types: synovial fibroblasts
Tested Concentrations: 1-30 μM
Incubation Duration: 24 hrs (hours)
Experimental Results: IL-6 and VCAM-1 gene expression was downregulated in synovial fibroblasts.

Animal/Disease Models: Female Lewis rat, 6-8 weeks old, approximately 150 g (rat collagen-induced arthritis) [1]
Doses: 25, 50 and 75 mg/kg
Route of Administration: Po; one time/day for 6 Day
Experimental Results: Prevents swelling and inflammation of ankle and knee joints.

---

Compound Formulation:** RVX-297 was formulated for oral administration in formulation EA006. The concentration of the test compound in each preparation was verified by LC/MS/MS. [1]
* **LPS Induced Endotoxemic Mouse Model:** Eight-week-old male C57Bl/6 mice received LPS by intraperitoneal injection. RVX-297 was administered orally at 75 mg/kg 4 hours before and again at the time of LPS stimulation. For serum cytokine determinations, animals received 5 μg of LPS, and serum was collected 4 hours post-LPS. For gene expression analysis, animals received 10 μg of LPS, and spleens were collected 3 hours post-LPS. [1]
* **Rat Collagen-Induced Arthritis (rCIA):** Female Lewis rats (6-8 weeks old) were immunized with bovine type II collagen emulsified with incomplete Freund's adjuvant (IFA) via intradermal injection on day 0, with a booster on day 7. Beginning on day 11 (arthritis phase), RVX-297 was administered orally twice per day (b.i.d.) for 6 days at 25, 50, and 75 mg/kg/dose. Efficacy was evaluated by body weight, ankle diameter measurement, histopathology of ankle and knee, and gene expression/cytokine levels in the ankle. [1]
* **Mouse Collagen Antibody Induced Arthritis (mCAIA):** Female BALB/cAnNHsd mice were injected intravenously with a cocktail of four arthritogenic monoclonal antibodies to collagen-II. After 24 hours, mice received 25 μg of LPS by intraperitoneal injection. Twice per day oral administration of RVX-297 (150 mg/kg) was initiated 30 hours following LPS and continued for 9 days. Efficacy was evaluated by body weight, clinical arthritis scores, combined hind paw weights, and histologic assessment. [1]
* **Murine Experimental Autoimmune Encephalomyelitis (EAE):** EAE was induced in female C57Bl/6 mice by immunization with myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35-55) in complete Freund's adjuvant (CFA). Pertussis toxin was administered by intraperitoneal injection 2 and 24 hours after immunization. RVX-297 was delivered by oral gavage at 75 and 125 mg/kg twice per day (b.i.d.) for 18 days in a therapeutic regimen (starting at the first sign of EAE) or for 27 days in a preventative regimen (starting immediately after immunization). In the therapeutic regimen, the 125 mg/kg dose was adjusted to 100 mg/kg b.i.d. on day 10 due to tolerability. EAE development and clinical score were evaluated based on clinical manifestations, and spinal cords were collected for gene expression analysis, flow cytometry, and histological assessment. [1]

[1]. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease. Mol Pharmacol. 2017;92(6):694-706.

[2]. RVX-297- a novel BD2 selective inhibitor of BET bromodomains. Biochem Biophys Res Commun. 2016;477(1):62-67.

C24H29N3O4

423.504766225815

423.215

1044871-04-6

135567084

White to light brown solid powder

3.5

1

6

7

31

639

0

O(C1C(C)=CC(C2=NC3C=C(C=C(C=3C(N2)=O)OC)OC)=CC=1C)CCN1CCCC1

PQZDYFRDRHRZGF-UHFFFAOYSA-N

InChI=1S/C24H29N3O4/c1-15-11-17(12-16(2)22(15)31-10-9-27-7-5-6-8-27)23-25-19-13-18(29-3)14-20(30-4)21(19)24(28)26-23/h11-14H,5-10H2,1-4H3,(H,25,26,28)

2-[3,5-dimethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,7-dimethoxy-3H-quinazolin-4-one

RVX-297 RVX297 RVX 297

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ~50 mg/mL (~118.06 mM)

Solubility in Formulation 1: ≥ 2.08 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.08 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

View More

Solubility in Formulation 3: ≥ 2.08 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

 (Please use freshly prepared in vivo formulations for optimal results.)